Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.895 USD | -0.13% | -6.02% | +4.28% |
Business Summary
Number of employees: 181
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cellular Immunotherapies
100.0
%
| 96 | 100.0 % | 64 | 100.0 % | -34.03% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 96 | 100.0 % | 64 | 100.0 % | -34.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
Chairman | 76 | 11-10-31 | |
Wen Bo Wang
CTO | Chief Tech/Sci/R&D Officer | - | 18-10-07 |
Bahram Valamehr
CTO | Chief Tech/Sci/R&D Officer | 47 | 18-07-31 |
Jerome C. Bressi
LAW | General Counsel | - | 18-11-30 |
Cindy Tahl
LAW | General Counsel | 51 | 08-12-31 |
Jim Beitel
PRN | Corporate Officer/Principal | - | 17-09-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
Chairman | 76 | 11-10-31 | |
John Mendlein
FOU | Founder | 64 | 07-04-26 |
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Michael Lee
BRD | Director/Board Member | 45 | 18-07-30 |
Karin Jooss
BRD | Director/Board Member | 59 | 19-03-13 |
Shefali Agarwal
BRD | Director/Board Member | 50 | 19-07-14 |
Yuan Xu
BRD | Director/Board Member | 56 | 21-08-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 113,831,969 | 112,032,716 ( 98.42 %) | 0 | 98.42 % |
Stock B | 0 | 2,761,108 | 0 | 0 |
Company contact information
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
92131, San Diego
+858 875 1800
http://www.fatetherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.28% | 444M | |
+9.96% | 115B | |
+11.92% | 106B | |
-2.59% | 21.96B | |
-12.51% | 21.87B | |
-5.29% | 19.21B | |
-3.85% | 18.08B | |
-38.57% | 17.71B | |
+6.97% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- FATE Stock
- Company Fate Therapeutics, Inc.